Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline reports positive data from Relovair trials

GlaxoSmithKline reports positive data from Relovair trials

10th January 2012

GlaxoSmithKline has completed a phase III registration programme for Relovair, a new respiratory disease treatment developed alongside Theravance.

Initial outcomes have been reported from all studies conducted among chronic obstructive pulmonary disease (COPD) patients and all but one of the drug's pivotal asthma trials.

In both patient groups, statistically significant improvements were shown to be provided by Relovair, a once-daily inhaled corticosteroid/long-acting beta-agonist combination treatment, containing fluticasone furoate and vilanterol.

GlaxoSmithKline intends to use this data to support regulatory applications for the as-yet unapproved therapy for both COPD and asthma in Europe.

Darrell Baker, senior vice-president and respiratory portfolio optimisation leader at GlaxoSmithKline, said: "We are pleased to have reached this milestone for Relovair, one of the important assets in our respiratory development portfolio."

Earlier this month, it was announced that GlaxoSmithKline's chief executive officer Andrew Witty has received a knighthood as part of the New Year's Honours List.ADNFCR-8000103-ID-801259816-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.